Nothing new in FDA clarification on GLP-1 compounding (but good reminder)

The FDA chose April Fool’s Day to issue an update clarifying its “policies for compounders as the national GLP-1 supply begins to stabilize.” The timing? Fitting, because after a close read, there’s not much here that isn’t already in existing guidance. As APC’s Scott Brunner noted on LinkedIn, every statement in the alert appears to be current policy pulled directly from FDA’s “essentially a cop” guidance – restated, not revised.

The one elaboration worth flagging was FDA’s naming of a cyanocobalamin and semaglutide combo as an example of what it considers an essentially a copy formulation. That’s not a new policy, but it does signal the agency is paying attention to specific combinations. Compounders using forms of vitamin B that are not commercially available in their GLP-1 formulations appear to be on firmer ground under a straight reading of the guidance – but this is a good moment to ensure you understand where the lines are drawn.

Bottom line: nothing changes, but the FDA clearly wants you to know what the rules are. Consider an April Fool’s update your reminder.